# ANG1005 in Patients With Recurrent High-Grade Glioma

> **NCT01967810** · PHASE2 · COMPLETED · sponsor: **Angiochem Inc** · enrollment: 73 (actual)

## Conditions studied

- Glioma
- Glioblastoma
- Brain Tumor, Recurrent

## Interventions

- **DRUG:** ANG1005
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01967810
- **Lead sponsor:** Angiochem Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2016-02
- **Final completion:** 2017-09
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01967810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01967810, "ANG1005 in Patients With Recurrent High-Grade Glioma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01967810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*